Glecaprevir + pibrentasvir for treatment of hepatitis C
| العنوان: | Glecaprevir + pibrentasvir for treatment of hepatitis C |
|---|---|
| المؤلفون: | Andres F. Carrion, Paul J. Martin |
| المصدر: | Expert Opinion on Pharmacotherapy. 19:413-419 |
| بيانات النشر: | Informa UK Limited, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Cyclopropanes, Aminoisobutyric Acids, Pyrrolidines, Proline, Lactams, Macrocyclic, viruses, Hepatitis C virus, medicine.disease_cause, Antiviral Agents, 03 medical and health sciences, 0302 clinical medicine, Leucine, Quinoxalines, medicine, Humans, Protease Inhibitors, Pharmacology (medical), 030212 general & internal medicine, NS5A, Pharmacology, Clinical Trials as Topic, Sulfonamides, NS3, business.industry, virus diseases, General Medicine, Hepatitis C, Glecaprevir, biochemical phenomena, metabolism, and nutrition, medicine.disease, Virology, digestive system diseases, Pibrentasvir, Regimen, Treatment Outcome, Benzimidazoles, Drug Therapy, Combination, 030211 gastroenterology & hepatology, Glecaprevir / pibrentasvir, business, Half-Life |
| الوصف: | Glecaprevir/pibrentasvir is a fixed-dose combination regimen of a new generation NS3/4A inhibitor and an NS5A inhibitor with potent antiviral activity against all hepatitis C virus (HCV) genotypes. This regimen offers a shorter course of therapy (8 weeks) for selected patients regardless of genotype and has demonstrated high virological efficacy for retreatment of individuals who previously failed an NS5A containing regimen. Glecaprevir and pibrentasvir are minimally excreted by the kidneys; thus this regimen can safely be used in individuals with severe chronic kidney disease (CKD), including those undergoing hemodialysis. Areas covered: This review covers the mechanism of action, pharmacokinetics, clinical applications, efficacy, and safety profile of glecaprevir/pibrentasvir. It also covers key phase 2 and 3 clinical trials that led to licensure of this regimen. Expert opinion: Glecaprevir/pibrentasvir is the latest antiviral regimen licensed in the United States for treatment of HCV infection. Although several other direct-acting antiviral agents (DAAs) are currently available, glecaprevir/pibrentasvir has some unique characteristics that expand treatment options for HCV infection, including patients with comorbidities such as advanced stage CKD or prior treatment failure to antiviral regimens containing other DAAs. |
| تدمد: | 1744-7666 1465-6566 |
| DOI: | 10.1080/14656566.2018.1444030 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::734f9ffb7e20488ee6c7ca625247c60a https://doi.org/10.1080/14656566.2018.1444030 |
| رقم الانضمام: | edsair.doi.dedup.....734f9ffb7e20488ee6c7ca625247c60a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 17447666 14656566 |
|---|---|
| DOI: | 10.1080/14656566.2018.1444030 |